دورية أكاديمية
Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.
| العنوان: | Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy. |
|---|---|
| المؤلفون: | Jones, James, Lucey, Rebecca, Corrie, Pippa |
| بيانات النشر: | Wiley //dx.doi.org/10.1111/pcmr.13067 Pigment Cell Melanoma Res |
| سنة النشر: | 2022 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | BRAF, dabrafenib, encorafenib, immunotherapy, melanoma, Humans, Proto-Oncogene Proteins B-raf, Retrospective Studies, Molecular Targeted Therapy, Neoplasms, Second Primary, Mutation, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols |
| الوصف: | BRAF-mutant melanoma patients can theoretically access both immunotherapy and BRAF-targeted therapy as treatment for metastatic disease. BRAF-targeted therapy is increasingly used 1st line for poorer prognostic patients, so we wanted to assess realistic expectations of these patients accessing 2nd-line immunotherapy. We conducted a retrospective review of clinical outcomes in 25 patients treated over the last 3 years with 1st-line BRAF-targeted therapy in a real-world clinical setting at a UK-based tertiary centre. Compared with the registration trials, our patients receiving 1st-line BRAF-targeted therapy had poorer performance status, higher disease burden, shorter median progression-free survival (5.05 months, 95% CI: 3.96-8.88) and shorter median overall survival (11.5 months, 95% CI: 6.24 - not reached). Overall response rate was similar, at 64%. On disease progression, median survival was 2.34 months (95% CI: 1.62 - not reached). Only five patients went on to receive 2nd-line immunotherapy. Metastatic melanoma patients treated with 1st-line BRAF-targeted therapy now have different demographics compared with those recruited to registration trials conducted over the last 10 years. In a modern-day, real-world setting, these patients should be counselled that only 1 in 5 are likely to receive 2nd-line immunotherapy and their survival times are expected to be short. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text/xml; application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/341367Test |
| DOI: | 10.17863/CAM.88793 |
| الإتاحة: | https://doi.org/10.17863/CAM.88793Test https://www.repository.cam.ac.uk/handle/1810/341367Test |
| رقم الانضمام: | edsbas.5C7DF4B0 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.88793 |
|---|